Intersect ENT to Report Fourth Quarter and Year 2018 Financial Results

MENLO PARK, Calif.–(BUSINESS WIRE)–Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the
quality of life for patients with ear, nose and throat conditions, today
announced that it will release fourth quarter and year 2018 financial
results on February 25, 2019. The company expects to issue the release
at approximately 4:00 p.m. ET and management will host a conference call
at 4:30 p.m. ET.

To access the conference call via the internet, go to the “Investor
Relations” page of the company’s website at
To access the live conference call via phone, dial (844) 850-0548 and
ask to join the Intersect ENT call. International callers may access the
live call by dialing (412) 317-5205. Participants may expedite telephone
access by pre-registering for the call using the following link:

A replay of the conference call may be accessed one to two hours after
the call at
or via phone at (877) 344-7529, or (412) 317-0088 for international
callers. The reference number to enter the replay of the call is
10128610. The dial-in replay will be available for a week after the
call, and via the internet for approximately one month.

About Intersect ENT®

Intersect ENT is dedicated to transforming ear, nose and throat care by
providing innovative, clinically meaningful therapies to physicians and
patients. The company’s steroid releasing implants are designed to
provide mechanical spacing and deliver targeted therapy to the site of
disease. In addition, Intersect ENT is continuing to expand its
portfolio of products based on the company’s unique localized steroid
releasing technology and is committed to broadening patient access to
less invasive and more cost-effective care.

For additional information on the company or the products, including
risks and benefits, please visit



Jeri Hilleman